Our Terms of Service and Privacy Policy have changed.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.
| 80.77 Delayed Data As of Jul 21 |  +0.63 / +0.79%Today’s Change | 53.15 Today|||52-Week Range 81.08 | +36.46% Year-to-Date |
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
| Asset Advisors Corp Buys Schwab International Equity, dorma+kaba Holding AG, ABB, Sel... Jul 20 / GuruFocus News - Paid Partner Content | Pinnacle Advisory Group, Inc. Buys Real Estate Select Sector SPDR Fund (The), SPDR Se... Jul 18 / GuruFocus News - Paid Partner Content |
| Howard Capital Management Buys iShares U.S. ... Jul 20 / GuruFocus News - Paid Partner Content | P.R. Herzig & Co. Inc. Buys Hanesbrands Inc, SPDR Series Trust S&P Biotech, Hexcel ..... Jul 18 / GuruFocus News - Paid Partner Content |
| Reilly Financial Advisors, Llc Buys Sensata Technologies Holding N.V. ... Jul 19 / GuruFocus News - Paid Partner Content | Foothills Asset Management, Ltd. Buys Whirlpool Corp, SPDR Series Trust S&P Biotech, ... Jul 17 / GuruFocus News - Paid Partner Content |
| 1 month | +2.87% | 3 years | +20.82% | |
| 3 months | +19.02% | 5 years | +22.10% | |
| 1 year | +37.60% | Since inception | +15.26% |
| Previous close | $80.14 |
| Open day’s range | 80.00 – 81.08 |
| Net asset value (NAV) | 80.75 (07/21/2017) |
| Daily volume | 3,230,207 |
| Average volume (3 months) | 4,233,326 |
| XBI | Category | |
|---|---|---|
| Performance 5-yr return | +22.10% | +17.39% |
| Expense Gross exp ratio | 0.35% | 1.33% |
| Risk 5 year sharpe ratio | 0.79 | 1.14 |
| Net assets | $3.5B | $3.0B |
| Average market cap | $4.6B | $30.8B |
| Average P/E | -- | 24.5 |
| Dividend / Share | -- | 0.30% |
| XLV Health Care Select Sector SPDR® Fund |
| RYH Guggenheim S&P 500® Equal Weight Health... |
| FHLC Fidelity® MSCI Health Care Index ETF |
| Healthcare | 100.00% |
| Business service | 0.00% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| CLVS Clovis Oncology Inc | 2.96% |
| EXEL Exelixis Inc | 2.44% |
| KITE Kite Pharma Inc | 2.26% |
| ALXN Alexion Pharmaceuticals Inc | 2.21% |
| CELG Celgene | 2.10% |
| ALNY Alnylam Pharmaceuticals Inc | 2.09% |
| GILD Gilead Sciences | 2.09% |
| SRPT Sarepta Therapeutics Inc | 2.05% |
| EXAS Exact Sciences Corp | 2.02% |
| INCY Incyte Corp | 2.02% |
